
Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

New polymer can stop biofilm formation
The acrylate co-polymer reported by Jean-Frédéric Dubern and colleagues in Science Advances (doi: 10.1126/sciadv.add7474) have the potential to...

Step Pharma presents promising cancer treatment
Since September 2022, STP938, the cancer inhibitor developed by Step Pharma SAS, has been undergoing clinical trials for the treatment of T and B...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

Vésale Bioscience wins R&D grant
Under the grant provided by the EIC Accelerator Fund for the PhageDiag project, Belgian Vésale Bioscience BV (Namur) will develop a phage therapy...

Neotiv GmbH closes €10m seed financing
In light of the high-profile Phase III Clarity trial results of Esai/Biogen's Alzheimer's protofibril inhibitor lecanemab, early diagnosis of...

EpiEndo Pharmaceuticals pushes COPD candidate
The Icelandic inflammation specialist received regulatory approval for its Phase IIa trial of Barriolide™ (EP395) in patients with Chronic...